This article discusses recent developments in the stem cell industry following Geron's exit from the field last month. While Geron's withdrawal shocked some, regenerative medicine experts were not surprised given challenges balancing risk profiles.
Recent data and financing activity indicate continued interest in stem cells. Nearly $23 billion has been raised by biotech companies in 2011 compared to $19 billion in 2010. Several regenerative medicine companies have completed private offerings raising over $30 million each. Clinical proof-of-concept data remains the greatest obstacle as investors seek evidence that stem cell therapies work. While hurdles remain, the stem cell field has been derisked in recent years through technical advances, though maintaining momentum will require creativity.